AIFF vs BTAI

For growth investors, BioXcel Therapeutics, Inc.

(BTAI) is the stronger pick with 64. 2% revenue growth year-over-year, versus -78. 3% for Firefly Neuroscience, Inc. (AIFF). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Firefly Neuroscience, Inc.

(AIFF) delivered a total return of -97. 5%, compared to -99. 7% for BioXcel Therapeutics, Inc. (BTAI). Over 10 years, the gap is even starker: AIFF returned -54. 8% versus BTAI's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Firefly Neuroscience, Inc.

(AIFF) is the lower-risk stock at 0. 48β versus BioXcel Therapeutics, Inc. 's 2. 64β — meaning BTAI is approximately 447% more volatile than AIFF relative to the S&P 500.

By revenue growth (latest reported year), BioXcel Therapeutics, Inc.

(BTAI) is pulling ahead at 64. 2% versus -78. 3% for Firefly Neuroscience, Inc. (AIFF). On earnings-per-share growth, the picture is similar: BioXcel Therapeutics, Inc. grew EPS 76. 1% year-over-year, compared to -384. 8% for Firefly Neuroscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioXcel Therapeutics, Inc.

(BTAI) is the more profitable company, earning -26. 3% net margin versus -96. 9% for Firefly Neuroscience, Inc. — meaning it keeps -26. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTAI leads at -29. 7% versus -85. 0% for AIFF. At the gross margin level — before operating expenses — AIFF leads at 38. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Firefly Neuroscience, Inc.

(AIFF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). BioXcel Therapeutics, Inc. (BTAI) carries a higher beta of 2. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIFF: -54. 8%, BTAI: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIFF (Technology) and BTAI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AIFF is a small-cap quality compounder stock; BTAI is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.